Vascular Anomalies Clinical Trial
Official title:
Phase I Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Marimastat in Patients With Disabling Malformations and No Other Treatment Options
3 patients were enrolled in each of 3 study cohorts. There three cohorts were given differing, incrementally larger doses of this phase I drug. The same safety measures are being obtained on all patients. Efficacy measures were individualized as enrolllees do not have the same underlying vascular anomaly. The study is structured to include a 24 month drug-phase and a 24 month follow-up phase. The study is now closed to enrollment.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06456125 -
Safety and Efficacy Of Amber Peripheral Liquid Embolic System
|
N/A | |
| Recruiting |
NCT04598204 -
Efficacy and Safety of Rapamycin to Complex Vascular Anomalies in Pediatric Patients
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05983159 -
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
|
Phase 2 |